Could a menopause drug combo cut breast cancer risk?
NCT ID NCT04821375
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This pilot study tested whether a daily combination of bazedoxifene and conjugated estrogens could change breast tissue markers in 16 women at increased risk for breast cancer. The women, aged 45-65 with menopausal symptoms, took the drugs for 6 months. The goal was to see if the approach is feasible and affects MRI and mammogram measures linked to cancer risk.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- bazedoxifene plus conjugated estrogens
- What this could lead to
- If successful, this could point toward a way to manage breast cancer risk while easing menopausal symptoms.
- What could go wrong
- This is a very small, early-phase pilot study with only 16 participants. It only tests feasibility and imaging changes, not cancer prevention, so results may not lead to a proven risk reduction.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for INCREASED RISK FOR DEVELOPMENT OF BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
University of Kansas Medical Center
Kansas City, Kansas, 66160, United States